Skip to main content
Addgene

pLX302 ID2-V5 puro
(Plasmid #83096)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 83096 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pLX302
  • Backbone manufacturer
    Addgene #25896
  • Backbone size w/o insert (bp) 9573
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Low Copy

Gene/Insert

  • Gene/Insert name
    ID2
  • Alt name
    inhibitor of DNA binding 2, HLH protein
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    405
  • GenBank ID
    NM_002166
  • Entrez Gene
    ID2 (a.k.a. GIG8, ID2A, ID2H, bHLHb26)
  • Tag / Fusion Protein
    • V5 (C terminal on backbone)

Cloning Information

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    Thermo Open Biosystems Human ORFeome version 5.1 #1362

Terms and Licenses

  • Academic/Nonprofit Terms
  • Industry Terms
    • Not Available to Industry
Trademarks:
  • Zeocin® is an InvivoGen trademark.

Depositor Comments

Plasmid for stable expression of human ID2 with C-terminal V5 tag.

How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pLX302 ID2-V5 puro was a gift from Kevin Janes (Addgene plasmid # 83096 ; http://n2t.net/addgene:83096 ; RRID:Addgene_83096)
  • For your References section:

    Tumor-Suppressor Inactivation of GDF11 Occurs by Precursor Sequestration in Triple-Negative Breast Cancer. Bajikar SS, Wang CC, Borten MA, Pereira EJ, Atkins KA, Janes KA. Dev Cell. 2017 Nov 20;43(4):418-435.e13. doi: 10.1016/j.devcel.2017.10.027. 10.1016/j.devcel.2017.10.027 PubMed 29161592